Biobot Analytics

+24%

est. 2Y upside i

HealthcareSeries A

Population health analytics powered by wastewater.

Rank

#1511

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

Due to critical missing financial data (revenue, growth rate, valuation), analysis confidence is low.

Last updated: July 19, 2026

Bull (20%)+100%

Government contracts expand, potential IPO or acquisition drives valuation to $120M+.

Base (55%)+30%

Steady revenue growth from municipal and federal contracts, valuation rises to $78M.

Bear (25%)-50%

Competition or funding challenges, exit value below $42.7M leads to common stock loss.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

Total funding $42.7M vs estimated valuation $60M (71% overhang)

Dilution Risk

moderate

Likely need to raise additional capital within 24 months, diluting common by ~20%

Secondary Liquidity

none

No secondary market observed

Questions to Ask at the Interview

Strategic questions based on Biobot Analytics's data — designed to show you've done your homework.

1
“How does Biobot's revenue growth trajectory compare to its government contract renewal rates?”
2
“What is the company's path to profitability and cash runway?”
3
“How does the equity package compare to public market equivalents in diagnostics?”

Our model estimates +24% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.